Scientists created a new experimental drug called A9 that combines a natural plant compound with a special molecule that releases nitric oxide (a gas your body naturally makes). In laboratory tests, this drug was extremely effective at killing stomach cancer cells. The drug works in two ways: it creates harmful molecules inside cancer cells that damage them from the inside out, and it interferes with how cancer cells get energy. While these results are exciting, the drug has only been tested in labs and in mice so far, not in people. More research is needed before doctors could ever use it to treat patients.
The Quick Take
- What they studied: Researchers wanted to see if a new experimental drug could kill stomach cancer cells better than existing treatments by using a combination of two different attack methods.
- Who participated: The study used stomach cancer cells grown in laboratory dishes and mice with stomach cancer tumors. No human patients were involved in this research.
- Key finding: The new drug (called A9) killed stomach cancer cells at extremely low doses—about 50 to 500 times smaller than what scientists typically need. In mice with tumors, the drug stopped tumor growth by 98.78%, which is nearly complete.
- What it means for you: This is very early-stage research that shows promise, but it’s important to understand this drug has never been tested in people. It could take many years of additional testing before it might become available as a treatment. Don’t consider this a cure or treatment option yet—it’s a laboratory discovery that needs much more research.
The Research Details
Scientists started with a natural compound called triptolidenol, which comes from a plant used in traditional medicine. They modified this compound by attaching a special molecule that releases nitric oxide (a gas your body naturally produces). They created several versions and tested them against stomach cancer cells grown in laboratory dishes to find the most effective one. Once they identified the best version (called A9), they studied exactly how it kills cancer cells by examining what happens inside the cells at a molecular level. Finally, they tested A9 in mice that had been given human stomach cancer tumors to see if it would work in a living organism.
This type of research is called “preclinical” because it happens before any human testing. Scientists use it to understand whether a potential drug is safe and effective enough to eventually test in people. The researchers used two different types of stomach cancer cells to make sure their results were consistent across different cancer variations.
This research approach is important because it combines traditional medicine knowledge with modern drug design. By understanding exactly how the drug works at the cellular level, scientists can predict whether it might be safe and effective in humans. Testing in both cells and animals gives researchers confidence that the drug does what they think it does, which is necessary before asking people to participate in clinical trials.
This study was published in a respected scientific journal that focuses on medicinal chemistry. The researchers used standard scientific methods and tested their drug multiple times to confirm results. However, this is laboratory research only—no human patients were involved. The study is limited because cancer cells in a dish don’t behave exactly like cancer in a real person’s body, and mice don’t always respond to drugs the same way humans do. Additionally, the researchers don’t provide information about potential side effects in living organisms, which is crucial information that would come from further testing.
What the Results Show
The new drug A9 was remarkably effective at killing stomach cancer cells in laboratory tests. Against one type of stomach cancer cell, it worked at a concentration of 0.10 micromolar (an extremely tiny amount). Against another type, it worked at just 0.02 micromolar—making it 50 to 500 times more powerful than the original plant compound it was based on.
The drug kills cancer cells through two simultaneous mechanisms. First, it releases nitric oxide, which creates harmful molecules called free radicals specifically inside the cancer cell’s mitochondria (the cell’s energy factories). This causes the mitochondria to malfunction and triggers the cell’s self-destruct program. Second, the drug interferes with how cancer cells produce the molecules they need to survive and protect themselves from damage. By disrupting both of these critical processes at once, the drug overwhelms the cancer cell’s defenses.
In mice with stomach cancer tumors, A9 was even more impressive. A dose of 15 milligrams per kilogram of body weight stopped tumor growth by 98.78%—meaning the tumors barely grew at all. This suggests the drug could potentially work in living organisms, not just in laboratory dishes.
The researchers discovered that A9 works by targeting specific enzymes (SHMT2 and MTHFD2) that cancer cells depend on for survival. These enzymes are part of a metabolic pathway that helps cancer cells generate energy and protect themselves from damage. By blocking these enzymes, the drug creates a situation where cancer cells can’t defend themselves against the harmful molecules the drug generates. This dual-action approach appears to be more effective than drugs that only attack cancer cells in one way.
The original plant compound (triptolidenol) had a problem: while it was safer and dissolved better in water than a related compound called triptolide, it wasn’t very good at killing cancer cells. By adding the nitric oxide-releasing component, scientists made it much more powerful—turning a moderately effective compound into an extremely potent one. This research builds on decades of work showing that natural plant compounds can be improved through chemical modification. The approach of combining nitric oxide release with metabolic pathway disruption appears to be novel and more effective than previous strategies.
This research has several important limitations. First, cancer cells in a laboratory dish don’t behave exactly like cancer in a living person—they don’t have to compete with a functioning immune system, and they don’t experience the complex environment of a human body. Second, mice respond to drugs differently than humans do, so results in mice don’t guarantee results in people. Third, the study doesn’t provide information about side effects or toxicity in living organisms, which is crucial for determining whether this drug could safely be given to patients. Fourth, the study doesn’t test how the drug would work alongside other treatments or in patients with drug-resistant cancers. Finally, we don’t know how long the drug would remain effective or whether cancer cells might eventually develop resistance to it.
The Bottom Line
Based on this laboratory research, there are no recommendations for patients at this time. This drug is not available for human use and should not be considered a treatment option. The appropriate next step is for other research groups to verify these findings and for scientists to conduct safety testing in animals before any human trials could begin. If you have stomach cancer, continue working with your oncologist on proven treatments. (Confidence level: This is very early-stage research—treat it as promising but highly preliminary.)
Researchers studying cancer treatment and pharmaceutical companies developing new drugs should pay attention to this work. Patients with gastric cancer and their families might find this interesting as a sign of ongoing research efforts, but should not expect this drug to become available soon. People interested in how natural plant compounds can be improved through chemistry may also find this research valuable. This research should NOT influence current treatment decisions for anyone with cancer.
If this drug follows the typical path from laboratory discovery to human treatment, it would likely take 5-10 years minimum before it could be tested in patients, and potentially 10-15 years before it might become available as a treatment (if it passes all safety and effectiveness testing). Many promising laboratory discoveries never make it to human use, so it’s important not to have unrealistic expectations.
Want to Apply This Research?
- Users interested in gastric cancer research could set a reminder to check for updates on this drug’s development every 6 months, tracking the progression from animal testing to clinical trials using a simple status log (e.g., ‘Lab stage,’ ‘Animal testing,’ ‘Clinical trials,’ ‘Approved’).
- For users with gastric cancer or family history of it, the app could encourage tracking of evidence-based preventive behaviors: maintaining a food diary to identify triggers, scheduling regular screenings as recommended by their doctor, and staying informed about clinical trials they might be eligible for.
- Create a ‘Cancer Research Updates’ section where users can follow the development of promising new treatments like A9. Include notifications when the drug advances to new testing phases, and provide links to clinical trial databases so users can check if they qualify for upcoming human studies.
This research describes an experimental drug that has only been tested in laboratory cells and mice. It is not approved for human use and is not available as a treatment. This article is for educational purposes only and should not be interpreted as medical advice. If you have been diagnosed with gastric or stomach cancer, please work with your oncologist to discuss proven treatment options. Do not delay or change your current cancer treatment based on this research. Always consult with qualified healthcare professionals before making any medical decisions. This drug may never become available for human use, as many promising laboratory discoveries do not advance to clinical use.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.